Anticoagulants Market Report 2023, Size, Share, Growth, Demand And Forecast Till 2028

 The latest report by IMARC Group, titled “Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global anticoagulants market size reached US$ 37.4 Billion in 2022 Looking forward, IMARC Group expects the market to reach US$ 67.0 Billion by 2028, exhibiting a growth rate (CAGR) of 10.1% during 2023-2028. 

Anticoagulants, also known as blood thinners, are medications or substances that prevent the formation of blood clots within the circulatory system. They prevent and treat conditions related to excessive blood clotting, which can be dangerous as they can block blood vessels, leading to severe health complications such as strokes or heart attacks. They target specific proteins in the blood, such as thrombin or factor Xa, which are essential for clot formation and inhibit these proteins to reduce the blood's ability to clot, making it less likely for clots to form and obstruct blood flow. Additionally, they are prescribed for various medical conditions, such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, and mechanical heart valve replacements. As a result, anticoagulants can be administered orally in pill form or through injections, depending on the needs of patients and the type of anticoagulant prescribed.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/anticoagulants-market/requestsample

Anticoagulants Market Trends and Drivers:

The anticoagulants market is primarily driven by the growing incidences of cardiovascular ailments. In addition, heart diseases and related conditions are escalating the demand for anticoagulants to prevent blood clots in individuals, thus contributing to the market growth. Moreover, ongoing research and development (R&D) efforts led to the introduction of novel and more effective anticoagulant drugs, representing another major growth-inducing factor. Besides this, the growing geriatric population is susceptible to atrial fibrillation and deep vein thrombosis, for which anticoagulants are prescribed as a standard treatment, thus accelerating the market growth. Along with this, the widespread adoption of direct oral anticoagulants (DOACs) is transforming anticoagulant therapy, thus propelling the market growth. DOACs offer advantages over traditional anticoagulants such as warfarin, including convenience, fewer dietary restrictions, and reduced monitoring requirements. Furthermore, governments and healthcare organizations are promoting the prevention and management of cardiovascular diseases, including initiatives to raise awareness and improve access to anticoagulant therapies, which are propelling the market growth.

Report Segmentation:

The report has segmented the market into the following categories:

Drug Class Insights:

• Novel Oral Anticoagulants (NOACs)
• Heparin and Low Molecular Weight Heparin (LMWH)
• Vitamin K Antagonist
• Others

Route of Administration Insights:

• Oral Anticoagulant
• Injectable Anticoagulant

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Application Insights:

• Atrial Fibrillation and Heart Attack
• Stroke
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• Alexion Pharmaceuticals Inc
• Aspen Holdings
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• Dr. Reddy’s Laboratories Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Private Limited
• Pfizer Inc.
• Sanofi

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA 

Follow us on Twitter: @imarcglobal